KAS
GANX icon

Kestra Advisory Services’s Gain Therapeutics GANX Stock Holding History

Kestra Advisory Services’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,000
Closed -$23.3K – 3297
2026
Q1 		$23.3K Hold
12,000
– – ﹤0.01% 3089
2025
Q4 		$38.6K Hold
12,000
– – ﹤0.01% 4124
2025
Q3 		$21.2K Buy
+12,000
New +$20.2K ﹤0.01% 2882

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PCM
Potomac Capital Management New York $147M AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Kestra Advisory Services's GANX Position: Q2 2026 in Review

Kestra Advisory Services sold out of Gain Therapeutics (GANX) in Q2 2026, closing a stake of 12,000 shares — an estimated $23.3K sold.

Kestra Advisory Services first reported a position in GANX in Q3 2025 and held it in 3 quarters. The position peaked at $38.6K in Q4 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

  • Kestra Advisory Services reported no remaining Gain Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Kestra Advisory Services sold 12,000 Gain Therapeutics shares in Q2 2026, an estimated $23.3K.
  • Kestra Advisory Services first reported a position in Gain Therapeutics in Q3 2025 and held it in 3 quarters.
  • Kestra Advisory Services's Gain Therapeutics position peaked at $38.6K in Q4 2025.
  • 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Kestra Advisory Services's 13F filing for Q2 2026, filed 28 Jul 2026.